fbpx

ADVERTISEMENT

ADVERTISEMENT

Myelodysplastic Syndrome

Updated : April 26, 2022



Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

azacitidine

Initial:

75

mg/m^2

Intravenous (IV)

once a day

7

days

of the 28-day cycle.
If no improvement is observed, the dose can be increased to 100 mg/m^2 IV.



decitabine

15

mg/m^2

Intravenous (IV)

over 3 hr

repeated every 8 hours for 3 days every 6 weeks



sargramostim 

It should be administered via IV infusions, the dose range is 15-500 mcg/m² per day. The infusion can be administered over 1-12 hours per day (every day) or 30-500 mcg/m² in a continuous infusion over 24 hours



luspatercept 

Indicated for Anemia-associated Myelodysplastic Syndromes in patients who require more than 2 RBC units over 8 weeks
Initially, 1 mg/kg subcutaneously once every 3 weeks
In the case of adverse reactions, do not increase the dose

Dose titration based on the insufficient response
If the RBC transfusion burden is not reduced after at least 6 weeks at 1 mg/kg, Increase the dose to 1.33 mg/kg every 3 weeks
If the RBC transfusion burden is not reduced after at least 6 weeks at 1.33 mg/kg, Increase the dose to 1.75 mg/kg every 3 weeks
If the RBC transfusion burden is not reduced after at least 9 weeks at 1.75 mg/kg, discontinue the treatment

Dosage modifications in the case of predose hemoglobin levels or a rapid hemoglobin rise
If predose hemoglobin is more than 11.5 g/dl in the absence of transfusions, prompt the dose and restart when hemoglobin goes less than 11 g/dl
When the hemoglobin is more than 2g/dl within 3 weeks (in the absence of transfusions)
If the current dose is 1.75 mg/kg, reduce it to 1.33 mg/kg
If the current dose is 1.33 mg/kg, reduce it to 1 mg/kg
If the current dose is 1.33 mg/kg, reduce it to 1 mg/kg
If the current dose is 1 mg/kg, reduce it to 0.8 mg/kg
If the current dose is 0.8 mg/kg, reduce it to 0.6 mg/kg
If the current dose is 0.6 mg/kg, discontinue the treatment



 
 

Media Gallary

References

Silicosis Cases Soar Among Young California Workers
News
Silicosis Cases Soar Among Young California Workers
Posted on
Brain Insulin Sensitivity Linked to Menstrual Cycle Phases
News
Brain Insulin Sensitivity Linked to Menstrual Cycle Phases
Posted on
Structured Meal Plans Might Elevate Preschoolers’ Nutritional Intake
News
Structured Meal Plans Might Elevate Preschoolers’ Nutritional Intake
Posted on
Migraine Genes Tied to Breast Cancer Risk
News
Migraine Genes Tied to Breast Cancer Risk
Posted on

ADVERTISEMENT 

Myelodysplastic Syndrome

Updated : April 26, 2022


azacitidine

Initial:

75

mg/m^2

Intravenous (IV)

once a day

7

days

of the 28-day cycle.
If no improvement is observed, the dose can be increased to 100 mg/m^2 IV.



decitabine

15

mg/m^2

Intravenous (IV)

over 3 hr

repeated every 8 hours for 3 days every 6 weeks



sargramostim 

It should be administered via IV infusions, the dose range is 15-500 mcg/m² per day. The infusion can be administered over 1-12 hours per day (every day) or 30-500 mcg/m² in a continuous infusion over 24 hours



luspatercept 

Indicated for Anemia-associated Myelodysplastic Syndromes in patients who require more than 2 RBC units over 8 weeks
Initially, 1 mg/kg subcutaneously once every 3 weeks
In the case of adverse reactions, do not increase the dose

Dose titration based on the insufficient response
If the RBC transfusion burden is not reduced after at least 6 weeks at 1 mg/kg, Increase the dose to 1.33 mg/kg every 3 weeks
If the RBC transfusion burden is not reduced after at least 6 weeks at 1.33 mg/kg, Increase the dose to 1.75 mg/kg every 3 weeks
If the RBC transfusion burden is not reduced after at least 9 weeks at 1.75 mg/kg, discontinue the treatment

Dosage modifications in the case of predose hemoglobin levels or a rapid hemoglobin rise
If predose hemoglobin is more than 11.5 g/dl in the absence of transfusions, prompt the dose and restart when hemoglobin goes less than 11 g/dl
When the hemoglobin is more than 2g/dl within 3 weeks (in the absence of transfusions)
If the current dose is 1.75 mg/kg, reduce it to 1.33 mg/kg
If the current dose is 1.33 mg/kg, reduce it to 1 mg/kg
If the current dose is 1.33 mg/kg, reduce it to 1 mg/kg
If the current dose is 1 mg/kg, reduce it to 0.8 mg/kg
If the current dose is 0.8 mg/kg, reduce it to 0.6 mg/kg
If the current dose is 0.6 mg/kg, discontinue the treatment



Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.

Facebook-f Twitter Instagram Youtube Linkedin Telegram

CONTACT INFORMATION

  • Telephone: 617-430-5616
  • General Inquiries: support@medtigo.com
  • State Licensing Services: Licensing@medtigo.com
  • Staffing Services: staffing@medtigo.com

ADDRESS

USA – BOSTON

60 Roberts Drive, Suite 313
North Adams, MA 01247

INDIA – PUNE

7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra

JOIN THE FASTEST GROWING HEALTHCARE COMMUNITY!

CREATE A NEW ACCOUNT

Download our APP

Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.

Facebook-f Twitter Instagram Youtube Linkedin Telegram

CONTACT INFORMATION

ADDRESS

MASSACHUSETTS – USA

60 Roberts Drive, Suite 313,
North Adams, MA 01247

MAHARASHTRA – INDIA

7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra

 

Taking the Pain out of Your Career

JOIN TODAY

DOWNLOAD APP

Free CME credits

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

Digital Certificate PDF

On course completion, you will receive a full-sized presentation quality digital certificate.

medtigo Simulation

A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

medtigo Points

medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
 
  • Registration with medtigo = 10 points
  • 1 visit to medtigo’s website = 1 point
  • Interacting with medtigo posts (through comments/clinical cases etc.) = 5 points
  • Attempting a game = 1 point
  • Community Forum post/reply = 5 points

    *Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.

All Your Certificates in One Place

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.

Our Certificate Courses

ACLS CERTIFICATION

  • 4.25 CME/CE Credits
  • Free ACLS Provider Card
  • 100% Online Training
  • Two Year Certification

BLS CERTIFICATION

  • 3 CME/CE Credits
  • Free BLS Provider Card
  • 100% Online Training
  • Two Year Certification

PALS CERTIFICATION

  • 4 CME/CE Credits
  • Free PALS Provider Card
  • 100% Online Training
  • Two Year Certification

NRP CERTIFICATION

  • 3 CME/CE Credits
  • Free NRP Provider Card
  • 100% Online Training
  • Two Year Certification